The Application Value of Spectral CT in the Accurate Staging of Breast Cancer

Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Adenocarcinoma

Age range

18 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(a) Chest quark energy spectrum CT examination was performed within 1 week before treatment
(b) Age ≥ 18
(c) Suspected breast cancer patients
(d) Patients who signed informed consent

Exclusion criteria

(a) Severe cardiac, pulmonary and renal insufficiency
(b) Allergic to iodine contrast media
(c) Unable to cooperate to complete CT examination
(d) Quark spectrum CT image is poor and cannot be used
(e) Male, pregnant and lactating female
(f) Combined with other tumor history
(g) Incomplete clinical and pathological data
(h) Pathologically confirmed non breast cancer

Treatment and study plan

To explore the value of spectral CT in the diagnosis and treatment of breast cancer

Diagnostic Test

The CT scan is part of the standard treatment protocol.

Primary outcomes

Pathological TNM staging

Time frame: 1 day

Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

Study contacts

Contact information is provided by the study sponsor or research team.

Caiyang Li

CONTACT

[email protected]

13658700171

Zhenhui Li

CONTACT

[email protected]

13698736132

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: May 18, 2025
Registry last updated: May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting